Myocardial resistance to ischemic and reperfusion injuries under conditions of chronic administration of opioid receptor agonists and antagonists.

Abstract

Chronic treatment with opioid receptor ligands: nonselective peptide opioid receptor agonist dalargin (intraperitoneally in a dose of 1 mg/kg), selective nonpeptide kappa-receptor agonist GR 89696 (subcutaneously in a dose of 0.03 mg/kg), nonselectrive nonpeptide antagonist quadazocine (subcutaneously in a dose of 3 mg/kg) or naltrexone (subcutaneously in a dose of 10 mg/kg) for 20 day had no effect of the incidence of ischemic ventricular arrhythmias and the size of necrotic zone after coronary occlusion and reperfusion in rats in vivo.

• Authors: Yu B Lishmanov, D L Stakheev, A V Krylatov, N V Naryzhnaya, L N Maslov, M V Ovchinnikov, F Kolar
• Journal: Bulletin of experimental biology and medicine (Bull Exp Biol Med) Vol. 145 Issue 6 Pg. 696-9 (Jun 2008) ISSN: 0007-4888 [Print] United States
• PMID: 19110553 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Azocines
• Narcotic Antagonists
• Piperazines
• Pyrrolidines
• Receptors, Opioid
• Receptors, Opioid, delta
• Receptors, Opioid, kappa
• Receptors, Opioid, mu
• GR 89696
• Naltrexone
• Enkephalin, Leucine-2-Alanine
• enkephalin-Leu, Ala(2)-Arg(6)-
• quadazocine

Topics

• Animals
• Azocines (pharmacology)
• Enkephalin, Leucine-2-Alanine (analogs & derivatives, pharmacology)
• Heart (drug effects, physiopathology)
• Male
• Myocardial Reperfusion Injury (prevention & control)
• Naltrexone (pharmacology)
• Narcotic Antagonists
• Piperazines (pharmacology)
• Pyrrolidines (pharmacology)
• Rats
• Rats, Wistar
• Receptors, Opioid (agonists)
• Receptors, Opioid, delta (agonists, antagonists & inhibitors)
• Receptors, Opioid, kappa (agonists, antagonists & inhibitors)
• Receptors, Opioid, mu (agonists, antagonists & inhibitors)